Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?

Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377:2226–35.

Bannwarth B, Kostine M, Shipley E. Nonspecific low back pain: assessment of available medications. Joint Bone Spine. 2012;79:134–6.

Woodcock J, Witter J, Dionne RA. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov. 2007;6:703–10.

Eibl JK, Strasser BC, Ross GM. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem Int. 2012;61:1266–75.

Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharm Sci. 2006;27:85–91.

Watson JJ, Allen SJ, Drawbarn D. Targeting nerve growth factor in pain. What is the therapeutic potential? Biodrugs. 2008;22:349–59.

Seidel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum. 2010;40:109–26.

Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage. 2013;21:1223–8.

Garber K. Fate of novel painkiller mAbs hangs in balance. Nat Biotechnol. 2011;29:173–4.

Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521–31.

Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13:790–8.

Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain. Results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65:1795–803.

Spierings ELH, Fidelholtz J, Wolfram G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154:1603–12.

Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2013 (in press).

Yazici Y, Ekman EF, Greenberg HS, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354) [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S828.

Tive L, Dabezies EJ, Fountaine RJ, et al. Long-term safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis (NCT00994890) [abstract]. Arthritis Rheum. 2013;65(Suppl 10):S911–2.

Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19:639–46.

Sanga P, Katz N, Polverejan E, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain. 2013;154:1910–9.

Tiseo P, Kivitz AJ, Ervin JE, et al. REGN475/SAR164877, a nerve growth factor inhibitor, in osteoarthritis patients with moderate to severe knee pain [abstract]. Arthritis Rheum. 2010;62(Suppl 10):S710.

Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152:2248–58.

Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154:1009–21.

Sanga P, Karcher K, Wang K, et al. Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe chronic low back pain [abstract]. J Pain. 2011;12(Suppl 4):P53.

Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm286552.htm , http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM301302.pdf (Accessed 28 Dec 2013).

Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2001;185:1716–21.

Nickel JC, Atkinson G, Krieger JN, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80:1105–10.

Wang H, Romano G, Frustaci ME, et al. Analgesic efficacy of fulranumab in patients with painful diabetic peripheral neuropathy in a randomized, placebo-controlled, double-blind study [abstract]. J Neurol Sci. 2013;333(Suppl 1):e522–3.

Bramson C, Herrmann D, Biton V, et al. Efficacy and safety of subcutaneous tanezumab in patients with pain related to diabetic peripheral neuropathy (NCT01087203) [abstract]. J Pain. 2013;14(Suppl 4):S68.

Romano G, Wang H, Ritz J, et al. Analgesic efficacy of fulranumab in patients with neuropathic pain in a randomized, placebo-controlled, double blind study. 14th World Congress on Pain, Milano; 2012, abstract PT452. http://www.abstracts2view.com/iasp/view.php?nu=107827&type=abstract (Accessed 28 Dec 2013).

Holmes D. Anti-NGF painkillers back on track? Nat Rev Drug Discov. 2012;11:337–8.

Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM307879.pdf (Accessed 15 Jan 2014).

Moss AC, Brinks V, Carpenter JF. Immunogenicity of anti-TNF biologics in IBD—the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38:1188–97.